ID   SJNB-5
AC   CVCL_8822
AS   CVCL_1446
SY   SJNB5; SJ-NB5; NB5; NB5-DH; NJF
DR   BTO; BTO:0005072
DR   CLO; CLO_0037088
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 949
DR   cancercelllines; CVCL_8822
DR   Cell_Model_Passport; SIDM00254
DR   ChEMBL-Cells; CHEMBL3308156
DR   ChEMBL-Targets; CHEMBL2366328
DR   Cosmic; 688080
DR   Cosmic; 922662
DR   Cosmic; 949176
DR   Cosmic; 947716
DR   Cosmic; 1037335
DR   Cosmic; 1099132
DR   Cosmic; 1153796
DR   Cosmic; 1526633
DR   Cosmic; 2131586
DR   Cosmic-CLP; 949176
DR   DepMap; ACH-002283
DR   EGA; EGAS00001000978
DR   GDSC; 949176
DR   GEO; GSM314023
DR   GEO; GSM333810
DR   GEO; GSM1670152
DR   IARC_TP53; 27183
DR   LINCS_LDP; LCL-1995
DR   PharmacoDB; NB5_991_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_8822
DR   PubChem_Cell_line; CVCL_8822
DR   Wikidata; Q54953577
RX   DOI=10.1007/0-306-46872-7_2;
RX   PubMed=6171342;
RX   PubMed=8516298;
RX   PubMed=10935473;
RX   PubMed=18923524;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: African American.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=87.26%; Native American=0%; East Asian, North=2.17%; East Asian, South=0%; South Asian=0.49%; European, North=5.14%; European, South=4.93% (PubMed=30894373).
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 13
ST   D16S539: 9,10
ST   D5S818: 12,13
ST   D7S820: 11
ST   TH01: 7,8
ST   TPOX: 8,11
ST   vWA: 16,19
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   2Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 30-01-24; Version: 34
//
RX   DOI=10.1007/0-306-46872-7_2;
RA   Thiele C.J.;
RT   "Neuroblastoma.";
RL   (In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999).
//
RX   PubMed=6171342;
RA   Brodeur G.M., Green A.A., Hayes F.A., Williams K.J., Williams D.L.,
RA   Tsiatis A.A.;
RT   "Cytogenetic features of human neuroblastomas and cell lines.";
RL   Cancer Res. 41:4678-4686(1981).
//
RX   PubMed=8516298; DOI=10.1073/pnas.90.12.5539;
RA   Johnson M.R., Look A.T., DeClue J.E., Valentine M.B., Lowy D.R.;
RT   "Inactivation of the NF1 gene in human melanoma and neuroblastoma cell
RT   lines without impaired regulation of GTP.Ras.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:5539-5543(1993).
//
RX   PubMed=10935473; DOI=10.1038/sj.neo.7900010;
RA   Kong X.-T., Valentine V.A., Rowe S.T., Valentine M.B., Ragsdale S.T.,
RA   Jones B.G., Wilkinson D.A., Brodeur G.M., Cohn S.L., Look A.T.;
RT   "Lack of homozygously inactivated p73 in single-copy MYCN primary
RT   neuroblastomas and neuroblastoma cell lines.";
RL   Neoplasia 1:80-89(1999).
//
RX   PubMed=18923524; DOI=10.1038/nature07399;
RA   Chen Y.-Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M.,
RA   Wang L.-L., Soda M., Kikuchi A., Igarashi T., Nakagawara A.,
RA   Hayashi Y., Mano H., Ogawa S.;
RT   "Oncogenic mutations of ALK kinase in neuroblastoma.";
RL   Nature 455:971-974(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//